Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUST: +61 294230881
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
5
Stocks News & Analysis
stocks
Strong finish to the year for overvalued ASX share
A great fiscal 2025 but investors are ahead of themselves.
stocks
Our three most overvalued ASX shares
These three companies are trading at a significant premium to our fair value.
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,080.70 | 39.80 | -0.44% |
CAC 40 | 7,749.39 | 14.55 | 0.19% |
DAX 40 | 23,718.45 | 88.68 | -0.37% |
Dow JONES (US) | 45,693.85 | 178.90 | 0.39% |
FTSE 100 | 9,242.53 | 21.09 | 0.23% |
HKSE | 25,938.13 | 304.22 | 1.19% |
NASDAQ | 21,856.45 | 57.75 | 0.26% |
Nikkei 225 | 43,459.29 | 184.52 | -0.42% |
NZX 50 Index | 13,253.73 | 27.41 | -0.21% |
S&P 500 | 6,508.89 | 13.74 | 0.21% |
S&P/ASX 200 | 8,803.50 | 37.40 | -0.42% |
SSE Composite Index | 3,807.29 | 19.55 | -0.51% |